FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Stack-Bibliothek

GH Max Stack

GH Optimizationadvanced

88

Synergie

88
Share
Peptide

3

Durchschnittliche tägliche mcg

25,586

Niveau

advanced

Hinzugefügt

May 17, 2026

Übersicht

The GH Max Stack represents the most aggressive non-exogenous approach to maximizing growth hormone output, combining three distinct mechanisms of GH stimulation. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog conjugated to a protein that extends its half-life to approximately 8 days. Unlike the no-DAC version, it provides a sustained elevation of baseline GH levels rather than discrete pulses, creating a continuously elevated "floor" of GH secretion throughout the week. MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist with a 24-hour half-life. It provides continuous GHS-R1a activation, complementing the sustained GHRH signaling from CJC-1295 with DAC. Clinical trials have demonstrated MK-677 increases IGF-1 levels by 40-60% in elderly subjects and improves nitrogen balance — a surrogate for anabolic activity. Daily Ipamorelin injections add targeted GH pulses on top of the elevated baseline, creating both sustained elevation and superimposed pulsatile peaks. This triple-mechanism approach produces GH and IGF-1 levels that approach or exceed physiological youth ranges. However, the advanced classification reflects significant considerations: MK-677 substantially increases appetite (via ghrelin pathway activation), may raise fasting blood glucose and HbA1c over time, and can cause water retention. The sustained GH elevation from CJC-1295 with DAC means less receptor recovery time compared to pulsatile protocols. This stack requires regular monitoring of fasting glucose, IGF-1 levels, and ideally HbA1c every 3 months. It is contraindicated in individuals with diabetes, pre-diabetes, active malignancy, or family history of pituitary tumors.

Dosierprotokoll

CJC-1295 (with DAC)

Once per week· subcutaneous

Weitere Informationen zu CJC-1295 (with DAC) →

2,000 mcg

pro Dosis

Ipamorelin

Every day· subcutaneous

Weitere Informationen zu Ipamorelin →

300 mcg

pro Dosis

MK-677 (Ibutamoren)

Every day· oral

Weitere Informationen zu MK-677 (Ibutamoren) →

25,000 mcg

pro Dosis

Ziele & Beweise

Maximum GH outputMuscle growthRecoveryIGF-1Body composition
Beweisstufe:Menschen RCT

Warnungen

  • MK-677 increases appetite significantly and may raise blood glucose. Not suitable for diabetics or pre-diabetics. CJC-1295/Ipamorelin remain FDA Category 2 (restricted) as of July 2026.

Comments

Sign in to join the discussion

Erklärung: Dieser Stack ist community-beigetragen und dient nur Forschungszwecken. Peptide Contacts überprüft die Sicherheit oder Effektivität beigetragener Stacks nicht. Bevor Sie irgendein Peptid-Protokoll einsetzen, beraten Sie sich stets mit einer qualifizierten Gesundheitskennzeichnung.